JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB96560

Anti-CD272/BTLA抗体

Anti-CD272/BTLA antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal CD272/BTLA antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human BTLA aa 1-200.

查看别名

CD272, B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein, BTLA

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD272/BTLA antibody (AB96560)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD272/BTLA antibody (AB96560)

ab96560, at a 1/100 dilution, staining CD272/BTLA in paraffin embedded MDAMB468 xenograft by Immunohistochemical analysis.

Western blot - Anti-CD272/BTLA antibody (AB96560)
  • WB

Unknown

Western blot - Anti-CD272/BTLA antibody (AB96560)

12% SDS PAGE

All lanes:

Western blot - Anti-CD272/BTLA antibody (ab96560) at 1/1000 dilution

Lane 1:

MOLT4 whole cell lysates at 30 µg

Lane 2:

Raji whole cell lysates at 30 µg

Predicted band size: 33 kDa

false

关键信息

宿主种属

Rabbit

克隆

Polyclonal

亚型

IgG

不含载体蛋白

No

反应种属

Human

应用

IHC-P, WB

applications

免疫原

Recombinant Fragment Protein within Human BTLA aa 1-200. The exact immunogen used to generate this antibody is proprietary information.

Q7Z6A9

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/500", "IHCP-species-notes": "<p></p>" } } }

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Immunogen
存储溶液
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
运输条件
Blue Ice
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

CD272 also known as BTLA (B and T Lymphocyte Attenuator) is an immunoregulatory protein with a mass approximately 34 kDa. This target is part of the CD28 immunoglobulin superfamily and is expressed on the surfaces of various immune cells including T cells B cells and dendritic cells. BTLA/CD272 serves as a co-inhibitory molecule important in maintaining immune homeostasis. Its expression is influenced by factors present in the microenvironment of immune tissues.
Biological function summary

BTLA functions as a negative regulator of immune responses by delivering inhibitory signals to immune cells upon binding to its ligand HVEM (Herpesvirus entry mediator). It forms a part of an immunological checkpoint complex that modulates lymphocyte activity to prevent overactivation and autoimmunity. This mechanism helps maintain a balance between immune defense and tolerance contributing to self-tolerance.

Pathways

The BTLA/CD272 protein engages with pathways involved in immune checkpoints and T-cell receptor signaling. It interacts with proteins like HVEM and collaborates with receptors such as PD-1 and CTLA-4. These interactions play a role in the downregulation of T-cell responses which is essential in various immune processes. The signaling pathways influenced by BTLA/CD272 are integral in moderating immune responses cooperation and adaptation.

BTLA is associated with autoimmune diseases and cancer. In autoimmune disorders an altered expression or function of BTLA can lead to dysregulated immune responses causing tissue damage. In cancer the protein may contribute to immune evasion by tumors aiding tumor growth and progression. The interplay of BTLA with proteins such as PD-1 makes it a potential target for immunotherapy strategies in oncology and autoimmunity treatments.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed : 12796776, PubMed : 14652006, PubMed : 15568026, PubMed : 18193050). May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14 (PubMed : 19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed : 19915044).
See full target information BTLA

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Blood 120:1412-21 PubMed22547582

2012

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Applications

IHC

Species

Human

Alan G Ramsay,Andrew J Clear,Rewas Fatah,John G Gribben
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com